Anika Therapeutics reports Q4 2024 revenue $30.6M, full year $119.9M; guides 2025 adj EBITDA margin 8-10%

Anika Therapeutics, Inc.

Q4 revenue from continuing ops $30.6M (+1% YoY); full-year revenue $119.9M (-1% YoY).
Commercial Channel revenue up 25% in Q4 ($10.9M) and 17% for full year ($42.1M).
Net loss from continuing ops: Q4 ($2.5M), ($0.17)/share; FY ($8.8M), ($0.60)/share.
FY 2025 guidance: Commercial Channel $47-49.5M (+12-18%), OEM Channel $64-68.5M (-12-18%).
Sale of Parcus Medical completed Mar 7; $5.6M in stock repurchased in Q4, $15M plan completed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.